Definium CCO granted 115,000 RSUs

Definium Therapeutics, Inc. granted its Chief Commercial Officer, Matthew T. Wiley, 115,000 common shares in the form of restricted stock units (RSUs).

Rhea-AI Filing Summary

Definium Therapeutics, Inc. granted its Chief Commercial Officer, Matthew T. Wiley, 115,000 common shares in the form of restricted stock units (RSUs). The grant was reported as an acquisition at a price of $0.00 per share, held directly by the officer.

Each RSU represents a contingent right to receive one common share of Definium Therapeutics. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, as long as Wiley continues providing service to the company on each vesting date.

Insider Trade Summary

Grant/Award: 115,000 shares

Grant/Award 1 txn

Insider Wiley Matthew T.

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	115,000	$0.00	$0.00

Holdings After Transaction: Common Shares — 115,000 shares (Direct)

Footnotes (1)

1. F1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Definium Therapeutics (DFTX) report for Matthew T. Wiley?

Definium Therapeutics reported that Chief Commercial Officer Matthew T. Wiley received 115,000 restricted stock units (RSUs) of common shares. The Form 4 filing shows these were acquired at $0.00 per share and are held directly by him as part of his compensation.

How many shares did the Definium Therapeutics CCO acquire in this Form 4 filing?

The Chief Commercial Officer of Definium Therapeutics acquired 115,000 restricted stock units. Each RSU represents a right to receive one common share, so this grant covers 115,000 common shares, subject to the vesting schedule and continued service conditions described in the filing.

What are the vesting terms of the 115,000 RSUs granted by Definium Therapeutics (DFTX)?

The 115,000 RSUs vest in 16 equal quarterly installments starting June 1, 2026. Vesting continues every quarter as long as Matthew T. Wiley remains in continuous service with Definium Therapeutics on each scheduled vesting date, according to the Form 4 footnote.

At what price were the Definium Therapeutics RSUs granted to the CCO?

The restricted stock units were granted at a reported price of $0.00 per share. This is typical for RSUs, which are usually awarded as equity compensation rather than purchased, with value realized as they vest into common shares over time.

How many Definium Therapeutics shares does Matthew T. Wiley own after this RSU grant?

Following the reported transaction, Matthew T. Wiley beneficially owns 115,000 common shares in the form of RSUs. These RSUs convert into actual shares as they vest, assuming he continues to provide service through each quarterly vesting date described in the filing.

Is the Definium Therapeutics (DFTX) RSU grant to the CCO a direct or indirect holding?

The Form 4 indicates the 115,000 restricted stock units are held as a direct ownership position. There is no reference to trusts, family entities, or disclaimers of beneficial ownership, so the grant is attributed directly to Matthew T. Wiley.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wiley Matthew T.

(Last) (First) (Middle)

C/O DEFINIUM THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, SUITE 8500

(Street)

NEW YORK NY 10007

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/03/2026		A		115,000(1)	A	$0.00	115,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date.

	/s/Mark Sullivan, Attorney-in-Fact for Matthew T. Wiley	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.